TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15078001
Drug: Ertapenem 1
Normalized name: ertapenem 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ertapenem 1 g daily
Study: 15164963
Drug: Piperacillin-tazobactam 3.375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin-tazobactam 3.375 g Q6H
Study: 7873470
Drug: Quinapril treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril treatment for 20 weeks
Study: 2450255
Drug: Enoximone (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone (150 mg t.d.s.)
Study: 2450255
Drug: Captopril (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (25 mg t.d.s.)
Study: 29299520
Drug: Inhalation lavender
Normalized name: LAVENDER
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhalation lavender aromatherapy
Study: 25801891
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (4000 IU, orally given as four gel capsules of 1000 IU)
Study: 20542923
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg TC-1734 (AZD3480)
Study: 17645482
Drug: Pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 40 mg b.i.d.
Study: 10200896
Drug: Propranolol (PROP,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (PROP, without ISA, 160 mg q.d.)
Study: 8383518
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg (R)-atenolol
Study: 8383518
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg (S)-atenolol
Study: 31978010
Drug: Sodium benzoate
Normalized name: Sodium Benzoate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium benzoate (400 mg/kg loading dose followed by 200 mg·kg·day maintenance for 5 days)
Study: 31978010
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical therapy with placebo
Study: 31353457
Drug: MDZ-NS 5
Normalized name: NS-2
DrugBank: Reproxalap (DB16688)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDZ-NS 5 mg (single dose)
Study: 31353457
Drug: MDZ-NS 5
Normalized name: NS-2
DrugBank: Reproxalap (DB16688)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDZ-NS 5 mg (second dose if needed)
Study: 17653742
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% bupivacaine (100 mg)
Study: 17653742
Drug: 0.125% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125% bupivacaine (50 mg)
Study: 11932297
Drug: GH (0.06
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH (0.06 mg/kg.d)
Study: 11932297
Drug: GH (0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH (0.03 mg/kg.d)
Study: 8554838
Drug: Progesterone pessaries
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progesterone pessaries (400 mg twice a day)
Study: 21063906
Drug: Corn gluten
Normalized name: AMINO ACIDS, CORN GLUTEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn gluten meal (CGM) at varying concentrations (0 to 200 g kg⁻¹)
Study: 25411976
Drug: H. pylori
Normalized name: H. PYLORI AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. pylori eradication therapy
Study: 12646971
Drug: Methylprednisolone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (10 mg/kg)
Study: 10883413
Drug: IVIG-L
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG-L
Study: 9179659
Drug: UFT adjuvant
Normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT adjuvant therapy (1:4 mixture of tegafur and uracil)
Study: 9179659
Drug: Nonadjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonadjuvant therapy
Study: 1490666
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone (rhGH) alone, 2.6 IU/m2 body surface area daily
Study: 1490666
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone (rhGH) alone, increased dose to 3.4 IU/m2 daily
Study: 1490666
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment with rhGH (3.4 IU/m2 daily) and reduced oxandrolone (0.05 mg/kg daily)
Study: 3966331
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg flecainide
Study: 14703955
Drug: FTY (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: FTY (0.25 - 3.5 mg)
Study: 14767029
Drug: FTY (3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: FTY (3.5 mg)
Study: 30075578
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg atorvastatin (conventional-dose), n=12
Study: 30075578
Drug: 40-80 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40-80 mg atorvastatin (intensive-dose), n=12
Study: 22992307
Drug: Protein pulse
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein pulse feeding (PD group, n=30), 72% of dietary protein (1.31 g/kg weight/d on average) consumed in one meal at noon.
Study: 16821426
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of atenolol and midodrine
Study: 16821426
Drug: Atenolol, Midodrine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol, Midodrine, and their combination
Study: 15228175
Drug: Standard Parent-Child
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Parent-Child Interaction Therapy (STD)
Study: 15228175
Drug: Abbreviated Parent-Child
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abbreviated Parent-Child Interaction Therapy (ABB)
Study: 12699020
Drug: No-treatment waitlist
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment waitlist control group (WL)
Study: 23313462
Drug: First-generation antipsychotics
Normalized name: benzethonium chloride / lidocaine hydrochloride Topical Gel [Tecnu First Aid]
Approvals — FDA: no, EMA: no, PMDA: no
Description: First-generation antipsychotics
Study: 29744871
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) dexketoprofen and metoclopramide
Study: 12567365
Drug: Noncontact normothermic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noncontact normothermic wound therapy (Warm‐UP; Augustine Medical Inc.) applied for 1 hour 3 times daily until healing or 12 weeks.
Study: 10598606
Drug: 1.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/kg rapacuronium
Study: 14576536
Drug: 1.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg/kg succinylcholine
Study: 1858703
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg valine.kg body wt‐1.d‐1 with 80 mg leucine.kg‐1.d‐1
Study: 1858703
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg valine.kg body wt‐1.d‐1 with 40 mg leucine.kg‐1.d‐1
Study: 6863097
Drug: Metoprolol (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (7 mg)
Study: 29053410
Drug: Low-dose exercise
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose exercise (8 kcal/kg of body weight per week)
Study: 29053410
Drug: High-dose exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose exercise (14 kcal/kg of body weight per week)
Study: 29053410
Drug: Moderate-intensity exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-intensity exercise (both doses)
Study: 26598423
Drug: Tolvaptan 45
Normalized name: tolvaptan 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolvaptan 45 mg per day
Study: 26562086
Drug: Psychoanalytic Child
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoanalytic Child Therapy (PaCT); approximately 20 psychotherapy sessions in various settings (parent-child, child-alone, parent-alone).
Study: 19671217
Drug: tDCS (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: tDCS (1 mA current strength, five treatment sessions, active or sham, given on alternate days)
Study: 7852133
Drug: Pilocarpine 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilocarpine 2.5 mg, 5.0 mg, and 10.0 mg tablets three times a day for 12 weeks (dose-titration study)
Study: 7852133
Drug: Pilocarpine 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilocarpine 5.0 mg and 10.0 mg tablets three times a day for 12 weeks (fixed-dose study)
Study: 7852133
Drug: Placebo (fixed-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (fixed-dose study)
Study: 30405296
Drug: Impaired homocysteine
Normalized name: mecysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Impaired homocysteine metabolism group (IHM, n=30)
Study: 30405296
Drug: Normal homocysteine
Normalized name: mecysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal homocysteine metabolism group (NHM, n=10)
Study: 26953629
Drug: LCPT (once-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCPT (once-daily extended-release tacrolimus tablets)
Study: 26953629
Drug: Tac BID
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tac BID (twice-daily tacrolimus capsules)
Study: 24300782
Drug: Somatropin (0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatropin (0.03 mg/kg/day)
Study: 21512661
Drug: (131)I treatment
Normalized name: IOBENGUANE I 123
Approvals — FDA: no, EMA: no, PMDA: no
Description: (131)I treatment
Study: 12030955
Drug: Essential fatty
Normalized name: essential fatty acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Essential fatty acids (gamma-linolenic acid 1.6 g, eicosapentaenoic acid 270 mg, docosahexaenoic acid 45 mg per day)
Study: 27517654
Drug: Prasugrel (20mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel (20mg loading dose, followed by 5mg maintenance dose daily)
Study: 27517654
Drug: Clopidogrel (300mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (300mg loading dose, followed by 75mg maintenance dose daily)
Study: 19567517
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (ZOL) 5 mg
Study: 15716709
Drug: Depressor therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depressor therapy (started ≤ 24 hours post-ictus)
Study: 15716709
Drug: Therapy (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy (both pressor and depressor)
Study: 9275461
Drug: 10mg mifepristone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg mifepristone daily
Study: 9275461
Drug: 20mg mifepristone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mg mifepristone daily
Study: 21508850
Drug: Other antipsychotics
Normalized name: Other antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other antipsychotics
Study: 30098152
Drug: Anlotinib (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib (12 mg/d)
Study: 400806
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg dapsone daily
Study: 400806
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg dapsone and 600 mg rifampicin daily for 6 months
Study: 26395085
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulphate (50 mg/kg bolus followed by 15 mg/kg/h infusion)
Study: 21236344
Drug: exemestane (EXE)
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: exemestane (EXE) 25 mg daily and celecoxib (CXB) 400 mg twice daily (group A)
Study: 21236344
Drug: exemestane (EXE)
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: exemestane (EXE) 25 mg daily (group B)
Study: 21236344
Drug: letrozole (LET)
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: letrozole (LET) 2.5 mg daily (group C)
Study: 8472625
Drug: Subcutaneous human
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous human proinsulin
Study: 8472625
Drug: Insulin zinc
Normalized name: insulin zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin zinc suspension
Study: 31305949
Drug: Existing treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Existing treatment (control group)
Study: 27165587
Drug: PS +
Normalized name: Spartan Nash 32 gauge 4 mm Pen Tips + 1C
Approvals — FDA: no, EMA: no, PMDA: no
Description: PS + continuous inhalation of budesonide aerosol
Study: 27165587
Drug: PS +
Normalized name: Spartan Nash 32 gauge 4 mm Pen Tips + 1C
Approvals — FDA: no, EMA: no, PMDA: no
Description: PS + budesonide solution
Study: 20962212
Drug: Canakinumab (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canakinumab (300 mg, subcutaneously)
Study: 17490781
Drug: Adjusted OAD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjusted OAD therapy
Study: 15699946
Drug: Cardioversion with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardioversion with subsequent use of antiarrhythmic drugs for maintenance of sinus rhythm
Study: 15699946
Drug: Antithrombotic drugs
Normalized name: Heparin group antithrombotic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombotic drugs (warfarin and aspirin)
Study: 15124545
Drug: Thermo-sensitive liposomes
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thermo-sensitive liposomes for carrying and targeting chemotherapeutics and gene therapies
Study: 19571282
Drug: Enalapril (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (20 mg daily)
Study: 15177063
Drug: Propranolol (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (180 mg daily)
Study: 11121909
Drug: Azithromycin 500
Normalized name: azithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 500 mg o.m. and tinidazole 500 mg b.d. during the first 3 days of pantoprazole therapy (early group, n=50)
Study: 11121909
Drug: Azithromycin 500
Normalized name: azithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 500 mg o.m. and tinidazole 500 mg b.d. during the last 3 days of pantoprazole therapy (late group, n=50)
Study: 1532117
Drug: Procaterol aerosol
Normalized name: procaterol
DrugBank: Procaterol (DB01366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procaterol aerosol (10 micrograms/inhalation), 2 inhalations t.i.d.
Study: 1532117
Drug: Albuterol (salbutamol)
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol (salbutamol) aerosol (100 micrograms/inhalation), 2 inhalations t.i.d.
Study: 30099422
Drug: Basic medical
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic medical treatment and allergen-specific immunotherapy (ASIT)
Study: 30099422
Drug: Basic medical
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic medical treatment only
Study: 8869763
Drug: Low-dose morphine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose morphine
Study: 20441717
Drug: Olanzapine OST
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine OST (10 mg od, 8 days)
Study: 15828904
Drug: Oral calcium
Normalized name: Coral Calcium
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral calcium carbonate plus vitamin D sterol (calcitriol or alfacalcidol)
Study: 9917117
Drug: Oral anticoagulation
Normalized name: monitoring agent for oral anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulation self-management group based on a structured treatment and teaching program and INR self-monitoring
Study: 35406
Drug: Thyrotropin-releasing hormone
Normalized name: thyrotropin-releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyrotropin-releasing hormone (TRH), 40 mg single dose
Study: 29798207
Drug: Nasal spray
Normalized name: Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal spray allergen blocker combined with oral antihistamine (citrate tablets)
Study: 27565398
Drug: Smoking Treatment
Normalized name: Pipe smoking tobacco
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking Treatment and Anxiety Management Program (STAMP)
Study: 15164511
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (ST) + placebo
Study: 11668360
Drug: Dipyrone (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyrone (600 mg oral dose)
Study: 9482291
Drug: High-dose isosorbide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose isosorbide dinitrate (3 mg bolus administered intravenously every 5 min)
Study: 9482291
Drug: High-dose furosemide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose furosemide plus low-dose isosorbide dinitrate
Study: 9482291
Drug: High-dose isosorbide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose isosorbide dinitrate
Study: 8305277
Drug: Gadodiamide injection
Normalized name: Gadodiamide
DrugBank: Gadodiamide (DB00225)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gadodiamide injection at a dose of 0.3 mM/kg (n = 7)
Study: 8305277
Drug: Gadopentetate dimeglumine
Normalized name: Gadopentetate Dimeglumine
DrugBank: Gadopentetic acid (DB00789)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gadopentetate dimeglumine at a dose of 0.1 mM/kg (n = 6)
Study: 3071485
Drug: Diet plus
Normalized name: Glucomannan/Grapefruit Extract/Pyridoxine Oral Tablet [GRAPEFRUIT DIET PLUS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet plus moderate exercise (3-mile walk, twice a week group sessions, once a week individual sessions)
Study: 29982544
Drug: Combined 2
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined 2 × 1000 mg/d omega-3 fatty acid and 50,000 IU/biweekly cholecalciferol supplement
Study: 27046347
Drug: Stent-retriever thrombectomy
Normalized name: castor fiber scent gland secretion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stent-retriever thrombectomy in combination with IV t-PA
Study: 22512875
Drug: Inorganic sunscreen
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inorganic sunscreen with SPF 8 at 0 mg cm(‐2) thickness
Study: 22512875
Drug: Inorganic sunscreen
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inorganic sunscreen with SPF 8 at 1 mg cm(‐2) thickness
Study: 22512875
Drug: Inorganic sunscreen
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inorganic sunscreen with SPF 8 at 1.5 mg cm(‐2) thickness
Study: 12126264
Drug: Telmisartan monotherapy
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telmisartan monotherapy (40 or 80 mg)
Study: 12126264
Drug: Telmisartan +
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telmisartan + HCTZ 12.5 mg
Study: 12126264
Drug: Telmisartan +
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telmisartan + HCTZ 25 mg
Study: 12126264
Drug: Telmisartan +
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telmisartan + another antihypertensive + HCTZ
Study: 12126264
Drug: Telmisartan monotherapy
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telmisartan monotherapy
Study: 1701072
Drug: Aprotinin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprotinin (2 x 10(6) KIU bolus before surgery, continuous infusion of 5 x 10(5) KIU/h during surgery, and additional 2 x 10(6) KIU to pump prime)
Study: 28732519
Drug: General skin-care
Approvals — FDA: no, EMA: no, PMDA: no
Description: General skin-care advice plus emollients applied daily for the first year of life
Study: 20361905
Drug: Olanzapine/fluoxetine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine/fluoxetine combination
Study: 10067662
Drug: L-carnitine (0.28
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (0.28 micromole/kg bw/minute)
Study: 321005
Drug: Parenteral penicillin
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Parenteral penicillin
Study: 29202549
Drug: Clonidine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.5 to 2.0 mg orally)
Study: 19596415
Drug: H5N1 inactivated
Normalized name: influenza, H5N1-1203
Approvals — FDA: no, EMA: no, PMDA: no
Description: H5N1 inactivated subvirion vaccine
Study: 15349011
Drug: Paroxetine 20
Normalized name: PARoxetine 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 20 mg/d for 18 days
Study: 2443619
Drug: 5-fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5-FU) 450 mg/m2 IV bolus daily for five days, then 200 mg/m2 IV bolus every other day for six doses
Study: 2443619
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) 50 mg/m2 IV infusion over four hours followed by IV bolus of 5-FU 600 mg/m2 weekly for 4 weeks and then every 2 weeks
Study: 2443619
Drug: Leucovorin 500
Normalized name: leucovorin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leucovorin 500 mg/m2 IV infusion with 5-FU 600 mg/m2 IV bolus one hour after Leucovorin every week for 6 weeks
Study: 21885490
Drug: VLD cyclobenzaprine
Approvals — FDA: no, EMA: no, PMDA: no
Description: VLD cyclobenzaprine (CBP) 1-4 mg at bedtime
Study: 9360512
Drug: [norleucine27]GHRH (1-29)-NH2
Approvals — FDA: no, EMA: no, PMDA: no
Description: [norleucine27]GHRH (1-29)-NH2 at a dose of 10 micrograms/kg
Study: 25170226
Drug: 160 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg/d PI-88
Study: 20719465
Drug: Bivalirudin (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalirudin (0.75 mg/kg intravenous bolus and intraprocedural infusion at 1.75 mg/kg/h)
Study: 20719465
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (100 UI/kg)
Study: 12526285
Drug: Tamsulosin (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin (0.2 mg) once daily for 24 weeks
Study: 12526285
Drug: Finasteride (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride (5 mg) once daily for 24 weeks
Study: 12526285
Drug: Tamsulosin (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin (0.2 mg) at 4 weeks